Search Results
Mar 03, 2026, 09:00 ET Investors Eye Explosive Growth in Anti-Aging Therapies as Market Targets $420B Milestone
markets this week include: Avaí Bio, Inc. (OTCQB: AVAI), Geron Corporation (NASDAQ: GERN), Intellia Therapeutics, Inc. (NASDAQ: NTLA), Niagen Bioscience, Inc. (NASDAQ: NAGE), Ocugen, Inc. (NASDAQ: OCGN).
More news about: Market News Updates
Nov 19, 2025, 17:31 ET KLKB1 Inhibitors Market to Reach New Heights by 2034 Owing to the Launch of Novel Therapies | DelveInsight
The recent approvals of EKTERLY as the first oral on-demand therapy and DAWNZTERA as the first RNA-based prophylactic, along with NTLA-2002 advancing into Phase III as a gene-editing therapy, underscore a shift in the pipeline toward greater treatment convenience, sustained efficacy,
More news about: DelveInsight Business Research, LLP
Oct 08, 2025, 17:31 ET Hereditary Transthyretin Amyloidosis Market Forecasts Strong Growth Amid New Treatment Launches | DelveInsight
in the market dynamics of hATTR. Intellia Therapeutics' Nexiguran ziclumeran (nex-z), also known as NTLA-2001, is an investigational in vivo CRISPR gene-editing therapy being developed by Intellia Therapeutics as a potential one-time treatment for transthyretin
More news about: DelveInsight Business Research, LLP